The acquisition includes 19 solid-oral dosage products.

The acquisition has been funded through cash on hand. Related StoriesANI acquires accepted ANDA for Flecainide Acetate tablets USPArthur S. Przybyl, President and CEO of ANI Pharmaceuticals, stated, ‘I am excited to add this group of approved products to our generic portfolio and to further leverage our manufacturing features. Importantly, we are manufacturing one of the initial products out of our containment facility for potent compounds. This acquisition meaningfully expands our product pipeline to 68 items with a total market value of $3.9B per IMS Health. We are delighted at the opportunity to increase our collaboration with Teva beyond the three transactions we’ve previously completed in the last eighteen months.’ Robert W.A complete of 17 participants from 15 mass media outlets visited institutes in the KBIC such as RIKEN Center for Developmental Biology , known because of its retinal regeneration research, and the Advanced Institute for Computational Research offering the K computer, one of the highest caliber of supercomputers in the world. At the CDB, Director Hiroshi Hamada and project leader Masayo Takahashi explained about the institute and its own world-first retinal transplant using iPS cells. Then, the tour participants noticed Takahashi's laboratory. The KBIC is one of the largest biomedical clusters in Japan where analysis institutes, greatly specialized hospitals and medical groups and companies are engaged in preliminary research and clinical application developments.